Glycomine has raised $115 million in a Series C round to advance its rare disease drug GLM101 into deeper clinical testing. The funding will support development for the treatment of PMM2-CDG, a genetic disorder affecting thousands of patients.
Glycomine has raised $115 million in a Series C round to advance its rare disease drug GLM101 into deeper clinical testing. The funding will support development for the treatment of PMM2-CDG, a genetic disorder affecting thousands of patients.
04/16/25, 12:03 PM
Location
san carlosMoney raised
$115 million
Round Type
series c
Glycomine, a biotechnology startup, has raised a $115 million Series C round to push its lead program deeper into clinical testing. The funding will support the development of its therapy GLM101, designed to treat PMM2-CDG, a rare genetic disorder. This funding is critical as there are no approved treatments for the condition, which affects a significant number of individuals in the U.S. and Europe
Company Info
Location
san carlos, california, united states
Additional Info
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. The company is based in San Carlos, California and supported by leading international life sciences investors. For more info, visit www.glycomine.com.